New York, New York (PRWEB) April 24, 2014
Lipitor lawsuits (http://www.thelipitorlawsuit.com/) that allege the popular statin drugs caused some patients to develop Type 2 diabetes continue to move forward in a federal multidistrict litigation now underway in U.S. District Court, District of South Carolina. According to court documents, the litigation’s next Status Conference will be convened on Friday, April 25, 2014. During the Conference, a number of issues will be addressed by the Court, including plans for the proceeding’s first bellwether trials. A proposed Joint Case Management Order indicates that those trials could begin as early as June 2015. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“We hear from Lipitor users on a regular basis who allegedly developed new-onset diabetes due to their use of this cholesterol-lowering statin. We are pleased to see the federal Lipitor lawsuits moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit reviews to individuals who took the statin and later developed Type 2 diabetes.
Lipitor and Diabetes
According to court documents, product liability lawsuits involving Lipitor and diabetes began to mount shortly after the U.S. Food & Drug Administration (FDA) announced in February 2012 that the labels of Lipitor and other statins would be updated to include new information about their potential association with Type 2 diabetes. The request followed the publication of a study in JAMA: Internal Medicine the previous month which suggested that post-menopausal women treated with statins faced an increased risk of developing new-onset Type 2 diabetes. *
Since then, evidence linking Lipitor and diabetes has mounted. For example, the British Medical Journal reported in May 2013 that atorvastatin, the active ingredient in Lipitor was linked to a 22 percent increased risk of new-onset diabetes.**
According to court documents, more than 400 Lipitor lawsuits have been filed in the federal litigation underway in the U.S. District Court, District of South Carolina since the litigation was established last year. Among other things, plaintiffs allege that Pfizer Inc. was aware of the link between Lipitor and diabetes prior to February 2012, but concealed this information in order to protect sales of the medication. The lawsuits further claim that many patients would never have used Lipitor had Pfizer provided adequate warnings regarding these risks, and assert that the warnings added to the drug’s label in 2012 remain inadequate.
Lipitor patients who allegedly developed diabetes due to their use of this medication may be entitled to compensation for the damages related to their injury. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to obtain a free legal review.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
**bmj.com/content/346/bmj.f2610, BMJ, May 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com